| ¿µ¹® | Graves' disease | ÇÑ±Û | ±×·¹À̺꽺º´ |
|---|---|---|---|
| ¼³¸í | °©»ó»ùÀÇ ºñ´ë¿Í °©»ó»ùÈ£¸£¸óÀÇ °ú´ÙºÐºñ°¡ Ư¡ÀÎ º´ÀÌ´Ù. ÀÌ º´Àº ÁÖ·Î 25~50¼¼¿¡ È£¹ßÇϰí ÁÖ·Î ¿©ÀÚ¿¡°Ô¼ ¸¹ÀÌ »ý±ä´Ù. °©»ó»ù È£¸£¸óÀº ÀúÀåµÇ¾î ÀÖ´Â ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ½ÅüÀÇ ´ë»çÀ²À» ³ôÀ̴ ȣ¸£¸óÀ̹ǷΠÀÔ¸ÀÀÌ ÁÁÀº µ¥µµ ºÒ±¸ÇÏ°í °è¼ÓÀûÀΠüÁßÀÇ °¨¼Ò, ±×¸®°í ÃàÀûµÈ ¿¡³ÊÁö¸¦ ¼Ò¸ðÇÏ¿© ¿»ý¸¹ÀÌ ÇÏ¿©¼ ´õÀ§¸¦ Âü±â Èûµé¾îÇÏ°í ¸¸¼º ¼è¾à°¨À̳ª ±Ù·ÂÀÇ ¾àȸ¦ º¸ÀÏ ¼ö°¡ ÀÖ´Ù. ±×¸®°í ´«¿¡ Ư¡ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³ª´Âµ¥ ´«²¨Ç®ÀÌ ºñÁ¤»óÀûÀ¸·Î À§·Î ¿Ã¶ó°¡ ÀÖ°í, ´«ÀÌ ¾Æ·¡ÀÇ ¹°°ÇÀ» ÁÖ½ÃÇÒ °æ¿ì¿¡ ´«²¨Ç®ÀÌ Á¤»óÀûÀ¸·Î´Â óÁ®¾ß ÇÏÁö¸¸ °©»ó»ù È£¸£¸óÀÌ °úµµÇÏ°Ô ³ª¿Ã °æ¿ì¿¡´Â ´«²¨Ç®ÀÌ Ã³ÁöÁö ¾Ê´Â´Ù. ¶Ç ´«¾ËÀÌ ¾ÕÂÊÀ¸·Î µ¹ÃâÇÏ´Â ¾È±¸µ¹ÃâÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¶Ç ÇǺΰ¡ ¾ÆÁÖ ºÎµå·´°í ¹°±â°¡ ¸¹¾Æ¼ ÃàÃàÇÏ´Ù. ±×¸®°í Ư¡ÀûÀ¸·Î ÇÏÁöÀÇ ¾ÕÂÊ¿¡ ÇǺΰ¡ µÎ²¨¿öÁ® ±¹¼ÒÀû À¶±â¸¦ ÀÌ·ç´Â °ÍÀÌ Àִµ¥ À̰ÍÀº ÀÌ º´ÀÇ Æ¯Â¡ÀûÀÎ º´ÅÍÀÌ´Ù. |
||
| ¿µ¹® | Raynaud disease | ÇÑ±Û | ·¹À̳뺴 |
|---|---|---|---|
| ¼³¸í | ±â´ÉÀû Ç÷°ü °æ·ÃÀ» ÀÏÀ¸Å°´Â º´À¸·Î °Ç°ÇÑ ÀþÀº ¿©¼ºÀÇ ÆÈ´Ù¸® ÀÛÀº µ¿¸ÆÀ» ħ¹üÇÑ´Ù. ÇÁ¶û½º ÀÇ»ç M.·¹À̳ë(1834~1881)°¡ º¸°íÇÑ °ÍÀ¸·Î ÀÌ º´Àº ÁÖ·Î ¼Õ°¡¶ô, ¼Õ, ¶§·Î´Â ÄÚ³¡À̳ª ¹ßµî, ¸öÀÇ ¸»´ÜºÎ ¼Òµ¿¸ÆÀ» ħ¹üÇÑ´Ù. Çѳðú °¨Á¤Àڱؿ¡ ÀÇÇÏ¸ç ¼Õ°¡¶ôÀº ¹é»öÀ¸·Î ´ÙÀ½Àº û»öÀ¸·Î, ±×¸®°í Àû»öÀ¸·Î º¯ÇÑ´Ù. ¿©¼º¿¡°Ô È£¹ßÇÑ´Ù. |
||
| ¿µ¹® | rheumatic heart disease | ÇÑ±Û | ·ù¸¶Æ¼½º½ÉÀ庴 |
|---|---|---|---|
| ¼³¸í | »ç½½¾Ë±Õ°¨¿° ÈÄ »ý±â´Â ½ÉÀåÆÇ¸·º´ÀÌ´Ù. ¿øÀÎÀº A±º -¿ëÇ÷»ç½½¾Ë¿¡ ÀÇÇÑ Àεο°ÈÄ ÀÏÁ¾ÀÇ ¸é¿ª¹ÝÀÀÀ¸·Î ¹ßº´ÇÑ´Ù. Áø´ÜÀº Á¸ÀÇ ±âÁØ¿¡ ÀÇÇÑ´Ù. (1) ÁÖ¿ä±âÁØÀº °üÀý¿° ½ÉÀå¿°(½ÉÀåºñ´ë, ½ÉÀåÀâÀ½, ½ÉÀå±â´É»ó½Ç µî) ¹«µµÁõ: ¹«´çÀÌ ÃãÀ» Ãß´Â °Í °°Àº ÇൿÀÇ ¹ßÀÛÁõ¼¼. ¿¬º¯È«¹Ý: »¡°£ Å׵θ®¸¦ °¡Áø ÇǺκ´º¯Àº ÇÇÇϰáÀý(subcutaneous nodule): ÇǺΠ¹Ø¿¡ »ý±ä °áÀý, (2)Âü°í ±âÁØÀº ¿, °üÀýÅë, EKG»ó PR¿¬Àå: ½ÉÀüµµ ¼Ò°ß ±Þ¼º±â ¹ÝÀÀ¹°Áú(¿¹: ESR, CRP)ÀÇ »ó½Â, ·ù¸¶Æ¼½º¿ Ä¡·á´Â Æä´Ï½Ç¸°À¸·Î Ä¡·áÇÏ°í ½ÉÀåÀÇ ÈÄÀ¯Áõ ¶ÇÇÑ Æä´Ï½Ç¸°À¸·Î ¿¹¹æÇÑ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | Buerger disease | ÇÑ±Û | ¹ö°Åº´ |
|---|---|---|---|
| ¼³¸í | ¸»ÃÊ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°´Â º´. ûÀå³âÃþÀÇ ³²ÀÚ¿¡°Ô Àß °É¸®´Â ´Ù¸® µ¿¸Æ¿¡ »ý±â´Â º´À¸·Î µ¿¸ÆÀÌ ¸·È÷°í ÅëÁõ ¶§¹®¿¡ ¹ßÀ» Àý±âµµ Çϴµ¥ ¿øÀÎÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. º´¸íÀº ÀÌ º´À» ÃÖÃÊ·Î »ó¼¼ÇÏ°Ô º¸°íÇÑ ¹Ì±¹ÀÇ ÀÇ»ç L. ¹ö°Å(1879~1943)ÀÇ À̸§¿¡¼ ¿¬À¯ÇÑ´Ù. µ¿¾çÀο¡°Ô ¸¹Àº º´À¸·Î, ´ëºÎºÐ ÀþÀº ³²¼º, ƯÈ÷ Àå³â±â ³²¼º¿¡°Ô¼ ³ªÅ¸³´Ù. ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª Èí¿¬ÀÌ º´ÀÇ ¾Çȸ¦ ÃÊ·¡ÇÑ´Ù. »çÁöÀÇ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀÌ ÀϾ Ç÷ÀüÀÌ »ý±â¸é ³»°À» ¸·¾Æ Ç÷¾×ÀÌ È帣Áö ¸øÇÏ°Ô µÇ¾î ±× ¾ÕÀÇ ¸»ÃÊÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁö°Å³ª ¼Õ¹ßÀÌ Â÷°©°í, ¼Õ°¡¶ô-¹ß°¡¶ôÀÌ º¸¶ó»ö ¶Ç´Â °ËÀº»öÀ¸·Î º¯ÇÑ´Ù. ¶Ç, ÀÌ Áõ¼¼°¡ °è¼ÓµÇ´Â µ¿¾È ¼Õ¹ß°¡¶ô¿¡ ÅëÁõÀÌ ÀϾ°í ±Ë¾çÀÌ ¹ß»ýÇÑ´Ù. Ä¡·á´Â Áõ¼¼ÀÇ Á¤µµ¿Í Æó»öµÈ Ç÷°üÀÇ ºÎÀ§¿¡ µû¶ó ¿¬°í¸¦ ¹Ù¸£°Å³ª Ç÷°üÈ®ÀåÁ¦-¼øÈ¯°³¼±Á¦-Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦¸¦ »ç¿ëÇϳª, ¾î¶² Ä¡·áµµ È¿°ú°¡ ¾øÀ» °æ¿ì ¼Õ¹ß°¡¶ôÀÇ ¼ÒÀý´Ü, µå¹°°Ô´Â ¹«¸ ÀÌÇÏÀÇ ´ëÀý´ÜÀ» ÇØ¾ß ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ º´ÀÇ ¿¹ÈÄ´Â ¾çÈ£ÇÏ¿© Ç÷·ù°¡ ȸº¹µÇ°í ±Ë¾ç¸¸ Ä¡·áµÇ¸é Àç¹ßÀÌ Àû´Ù. |
||
| PID | 1) Pelvic Inflammatory Disease; °ñ¹Ý ¿°Áõ¼º Áúȯ [Chap 89, HP 534-8] 2) Plasma I... |
|---|---|
| PID | pain intensity difference [score]; pelvic inflammatory disease; photoionization detector; picture im... |
| AD | accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade... |
| PD | Doctor of Pharmacy; Dublin Pharmacopoeia; interpupillary distance; Paget disease; pancreatic duct; p... |
| RD | radial deviation; radiology department; rate difference; Raynaud disease; reaction of degeneration; ... |
| tuberculous pericarditis | Pericarditis caused by tuberculosis infection. (05 Mar 2000) |
|---|---|
| tuberculous peritonitis | <radiology> Aetiology: haematogenous spread, rupture of mesenteric node, Types: wet: exudative ascites, dry: tuberculous adenopathy and adhesions, fibrotic: abdominal mass with separation and fixation of bowel, CT: high density ascites (30 HU), peripancreatic and mesenteric adenopathy with low density, centres (caseous necrosis), irregular soft tissue density of omemtum, ** tuberculosis: gastrointestinal manifestations (12 Dec 1998) |
| tuberculous rheumatism | An inflammatory condition of the joints or fibrous tissues during the course of tuberculosis. (05 Mar 2000) |
| tuberculous spondylitis | Tuberculous infection of the spine associated with a sharp angulation of the spine at the point of disease. Synonym: Pott's disease, spondylarthrocace, spondylocace, trachelocyrtosis, trachelokyphosis. (05 Mar 2000) |
| tuberculous wart | A tuberculous skin lesion having a warty surface with a chronic inflammatory base seen on the hands in adults and lower extremities in children, with marked hypersensitivity to tuberculous antigens. See: postmortem wart. Synonym: lupus papillomatosus, lupus verrucosus, tuberculous wart, verrucous scrofuloderma. (05 Mar 2000) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|